Clinical trial · Observational
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Comprehensive Study on the Quality of Life in Cervical Cancer Patients: A Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is prospective cohort study. All the patients with primary cervical cancer in the future three years in Peking Union Medical College Hospital will be included in this study. Before and after the major therapy (including at least radical hysterectomy and/or radiotherapy), the patients accept (1) the questionnaires survey about quality of life; (2) urodynamic testing; (3) rectum dynamics testing and (4) ovarian reserve function. The survival outcomes (disease-free survival and overall survival) will be supplemented as secondary objectives.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Disease-free Survival | — | UNRESOLVED | — |
| Ovarian Reserve Function | — | UNRESOLVED | — |
| Overall Survival | — | UNRESOLVED | — |
| Pelvic Floor Disorders | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Rectum Dynamics | — | UNRESOLVED | — |
| Sex Dysfunction | — | UNRESOLVED | — |
| Survivorship | — | UNRESOLVED | — |
| Urodynamics | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ovarian reserve function | Diagnostic Test | — | UNRESOLVED |
| questionnaires survey | Diagnostic Test | — | UNRESOLVED |
| Rectum dynamics testing | Diagnostic Test | — | UNRESOLVED |
| Urodynamic testing | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Scores from EORTC QLQ-C30
- timeFrame
- Change from the baseline of four weeks before major therapy at following-up. The standard scores ranges from 0 to 100, and the higher score, the more inferior quality of life.
- description
- Scores calculated from European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
- measure
- Scores from EORTC QLQ-CX24
- timeFrame
- Change from the baseline of four weeks before major therapy at following-up. The standard scores ranges from 0 to 100, and the higher score, the more inferior quality of life.
- description
- Scores calculated from EORTC QLQ-CX24
Secondary outcomes (15)
- measure
- Concentration of follicle-stimulating hormone
- timeFrame
- Change from the baseline of four weeks before major therapy at following-up
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primary uterine cervical carcinomas * Aged 18 or older * Accepting major therapy (including at least radical hysterectomy and/or radiotherapy) in the study center * Informed consents delivered Exclusion Criteria: * Not meeting any of the inclusion criteria * Not accepting any of the four kinds of evaluations for quality of life * Recurrent patients * Not achieving response after above major therapy
References
Publications (0)
Data not yet available